PIK3CB and diffuse large B-cell lymphoma: In patients with relapsed/refractory DLBCL the PI3Kδ inhibitor idelalisib showed only modest activity suggesting that more than one PI3K isoform has to be inhibited either due to functional redundancies or to prevent feedback mechanisms [22].